Antipneumococcal activity of neuraminidase inhibiting artocarpin

International Journal of Medical Microbiology

Volumn 305, Issue 3, 2015, Pages 289-297

  Walther, E ^a   Richter, M ^a   Xu, Z ^a   Kramer, C ^b   von Grafenstein, S ^b   Kirchmair, J ^c   Grienke, U ^b,d   Rollinger, J M ^d   Liedl, K R ^b   Slevogt, H ^a   Sauerbrei, A ^a   Saluz, H P ^e   Pfister, W ^a   Schmidtke, M ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c UNIVERSITY OF HAMBURG   (Germany)

^d UNIVERSITY OF VIENNA   (Austria)

^e HANS KNÖLL INSTITUTE   (Germany)

Author keywords

Antipneumococcal; Artocarpin; Biofilm; DANA; Katsumadain A; NanA; Neuraminidase; Neuraminidase inhibitors; Oseltamivir; Pneumococci; Zanamivir

Indexed keywords

ANTIBIOTIC AGENT; ARTOCARPIN; BACTERIAL ENZYME; FLAVONE; GENOMIC DNA; HEPTANE DERIVATIVE; KATSUMADAIN A; OSELTAMIVIR; RIFAMPICIN; SIALIDASE; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; VIRULENCE FACTOR; ZANAMIVIR;

A549 CELL LINE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL CELL; BACTERIAL GROWTH; BACTERIAL VIABILITY; BACTERICIDAL ACTIVITY; BACTERIUM ADHERENCE; BIOFILM; CC50; CELL VIABILITY; CHEMOLUMINESCENCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME INHIBITION; ESCHERICHIA COLI; HEMAGGLUTINATION; HEMOLYSIS; HUMAN; HUMAN CELL; IC50; INHIBITION CONSTANT; LUNG ALVEOLUS EPITHELIUM CELL; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PROTEIN EXPRESSION; STREPTOCOCCUS PNEUMONIAE;

EID: 84983590161     PISSN: 14384221     EISSN: 16180607     Source Type: Journal    
DOI: 10.1016/j.ijmm.2014.12.004     Document Type: Article

References (38)

1. Black R.E., Cousens S., Johnson H.L., Lawn J.E., Rudan I., Bassani D.G., Jha P., Campbell H., Walker C.F., Cibulskis R., Eisele T., Liu L., Mathers C., Unicef W. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 2010, 375:1969-1987.
2. Brittan J.L., Buckeridge T.J., Finn A., Kadioglu A., Jenkinson H.F. Pneumococcal neuraminidase A: an essential upper airway colonization factor for Streptococcus pneumoniae. Mol. Oral Microbiol. 2012, 27:270-283.
3. Burnaugh A.M., Frantz L.J., King S.J. Growth of Streptococcus pneumoniae on human glycoconjugates is dependent upon the sequential activity of bacterial exoglycosidases. J. Bacteriol. 2008, 190:221-230.
4. Chen G.Y., Chen X., King S., Cavassani K.A., Cheng J.S., Zheng X.C., Cao H.Z., Yu H., Qu J.Y., Fang D.X., Wu W., Bai X.F., Liu J.Q., Woodiga S.A., Chen C., Sun L., Hogaboam C.M., Kunkel S.L., Zheng P., Liu Y. Amelioration of sepsis by inhibiting sialidase-mediated disruption of the CD24-SiglecG interaction. Nat. Biotechnol. 2011, 29. 428-U234.
5. Collins P.J., Haire L.F., Lin Y.P., Liu J.F., Russell R.J., Walker P.A., Skehel J.J., Martin S.R., Hay A.J., Gamblin S.J. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature 2008, 453:1258-U1261.
6. French G.L. Bactericidal agents in the treatment of MRSA infections - the potential role of daptomycin. J. Antimicrob. Chemother. 2006, 58:1107-1117.
7. Grienke U., Schmidtke M., Kirchmair J., Pfarr K., Wutzler P., Durrwald R., Wolber G., Liedl K.R., Stuppner H., Rollinger J.M. Antiviral potential and molecular insight into neuraminidase inhibiting diarylheptanoids from Alpinia katsumadai. J. Med. Chem. 2010, 53:778-786.
8. Grienke U., Schmidtke M., von Grafenstein S., Kirchmair J., Liedl K.R., Rollinger J.M. Influenza neuraminidase: a druggable target for natural products. Nat. Prod. Rep. 2012, 29:11-36.
9. Gut H., Xu G.G., Taylor G.L., Walsh M.A. Structural basis for Streptococcus pneumoniae NanA inhibition by influenza antivirals zanamivir and oseltamivir carboxylate. J. Mol. Biol. 2011, 409:496-503.
10. Hsiao Y.S., Parker D., Ratner A.J., Prince A., Tong L. Crystal structures of respiratory pathogen neuraminidases. Biochem. Biophys. Res. Commun. 2009, 380:467-471.
11. Kash J.C., Walters K.A., Davis A.S., Sandouk A., Schwartzman L.M., Jagger B.W., Chertow D.S., Li Q., Kuestner R.E., Ozinsky A., Taubenberger J.K. Lethal synergism of 2009 pandemic H1N1 influenza virus and Streptococcus pneumoniae coinfection is associated with loss of murine lung repair responses. mBio 2011, 2. e00172-11.
12. Kelly R.T., Farmer S., Greiff D. Neuraminidase activities of clinical isolates of Diplococcus Pneumoniae. J. Bacteriol. 1967, 94:272-&.
13. King S.J., Hippe K.R., Gould J.M., Bae D., Peterson S., Cline R.T., Fasching C., Janoff E.N., Weiser J.N. Phase variable desialylation of host proteins that bind to Streptococcus pneumoniae in vivo and protect the airway. Mol. Microbiol. 2004, 54:159-171.
14. King S.J., Hippe K.R., Weiser J.N. Deglycosylation of human glycoconjugates by the sequential activities of exoglycosidases expressed by Streptococcus pneumoniae. Mol. Microbiol. 2006, 59:961-974.
15. Kirchmair J., Rollinger J.M., Liedl K.R., Seidel N., Krumbholz A., Schmidtke M. Novel neuraminidase inhibitors: identification, biological evaluation and investigations of the binding mode. Future Med. Chem. 2011, 3:437-450.
16. Krzysciak W., Pluskwa K.K., Jurczak A., Koscielniak D. The pathogenicity of the Streptococcus genus. Eur. J. Clin. Microbiol. 2013, 32:1361-1376.
17. Lofling J., Vimberg V., Battig P., Henriques-Normark B. Cellular interactions by LPxTG-anchored pneumococcal adhesins and their streptococcal homologues. Cell. Microbiol. 2011, 13:186-197.
18. McCullers J.A., Bartmess K.C. Role of neuraminidase in lethal synergism between influenza virus and Streptococcus pneumoniae. J. Infect. Dis. 2003, 187:1000-1009.
19. Nakano V., Maria R., Piazza F., Avila-Campos M.J. A rapid assay of the sialidase activity in species of the Bacteroides fragilis group by using peanut lectin hemagglutination. Anaerobe 2006, 12:238-241.
20. Nobbs A.H., Lamont R.J., Jenkinson H.F. Streptococcus adherence and colonization. Microbiol. Mol. Biol. Rev. 2009, 73:407-450.
21. Oggioni M.R., Trappetti C., Kadioglu A., Cassone M., Iannelli F., Ricci S., Andrew P.W., Pozzi G. Switch from planktonic to sessile life: a major event in pneumococcal pathogenesis. Mol. Microbiol. 2006, 61:1196-1210.
22. Okomo-Adhiambo M., Sleeman K., Ballenger K., Nguyen H.T., Mishin V.P., Sheu T.G., Smagala J., Li Y., Klimov A.I., Gubareva L.V. Neuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective. Viruses-Basel 2010, 2:2269-2289.
23. Orihuela C.J., Gao G.L., Francis K.P., Yu J., Tuomanen E.I. Tissue-specific contributions of pneumococcal virulence factors to pathogenesis. J. Infect. Dis. 2004, 190:1661-1669.
24. Parker D., Soong G., Planet P., Brower J., Ratner A.J., Prince A. The NanA neuraminidase of Streptococcus pneumoniae is involved in biofilm formation. Infect. Immun. 2009, 77:3722-3730.
25. Paulson J.C., Kawasaki N. Sialidase inhibitors DAMPen sepsis. Nat. Biotechnol. 2011, 29:406-407.
26. Pereira M.E.A. A Rapid and sensitive assay for neuraminidase using peanut lectin hemagglutination - application to Vibrio-cholera and Trypanosoma-cruzi. J. Immunol. Methods 1983, 63:25-34.
27. Pettigrew M.M., Fennie K.P., York M.P., Daniels J., Ghaffar F. Variation in the presence of neuraminidase genes among Streptococcus pneumoniae isolates with identical sequence types. Infect. Immun. 2006, 74:3360-3365.
28. Richter M., Schumann L., Walther E., Hoffmann A., Braun H., Grienke U., Rollinger J.M., Von Grafenstein S., Liedl K.R., Kirchmair J., Wutzler P., Sauerbrei A., Schmidtke M. Complementary assays for identifying neuraminidase inhibitors. Future Virol. 2015, (in press). 10.2217/FVL.14.97.
29. Schmidtke M., Schnittler U., Jahn B., Dahse H.M., Stelzner A. A rapid assay for evaluation of antiviral activity against coxsackie virus B3, influenza virus A, and herpes simplex virus type 1. J. Virol. Methods 2001, 95:133-143.
30. Simell B., Auranen K., Kayhty H., Goldblatt D., Dagan R., O'Brien K.L., Grp P.C. The fundamental link between pneumococcal carriage and disease. Expert Rev. Vaccines 2012, 11:841-855.
31. Singer B.B., Scheffrahn I., Kammerer R., Suttorp N., Ergun S., Slevogt H. Deregulation of the CEACAM expression pattern causes undifferentiated cell growth in human lung adenocarcinoma cells. PLoS One 2010, 5:e8747.
32. Soong G., Muir A., Gomez M.I., Waks J., Reddy B., Planet P., Singh P.K., Kanetko Y., Wolfgang M.C., Hsiao Y.S., Tong L., Prince A. Bacterial neuraminidase facilitates mucosal infection by participating in biofilm production. J. Clin. Invest. 2006, 116:2297-2305.
33. Taylor G. Sialidases: structures, biological significance and therapeutic potential. Curr. Opin. Struc. Biol. 1996, 6:830-837.
34. Tong H.H., Blue L.E., James M.A., DeMaria T.F. Evaluation of the virulence of a Streptococcus pneumoniae neuraminidase-deficient mutant in nasopharyngeal colonization and development of otitis media in the chinchilla model. Infect. Immun. 2000, 68:921-924.
35. Trappetti C., Kadioglu A., Carter M., Hayre J., Iannelli F., Pozzi G., Andrew P.W., Oggioni M.R. Sialic acid: a preventable signal for pneumococcal biofilm formation, colonization, and invasion of the host. J. Infect. Dis. 2009, 199:1497-1505.
36. Weisburg W.G., Barns S.M., Pelletier D.A., Lane D.J. 16S ribosomal DNA amplification for phylogenetic study. J. Bacteriol. 1991, 173:697-703.
37. Yadav M.K., Chae S.-W., Song J.-J. In vitro Streptococcus pneumoniae biofilm formation and in vivo middle ear mucosal biofilm in a rat model of acute otitis induced by S. pneumoniae. CEO 2012, 5:139-144.
38. Yu T., Malugin A., Ghandehari H. Impact of silica nanoparticle design on cellular toxicity and hemolytic activity. ACS Nano 2011, 5:5717-5728.